Seraphina Therapeutics is Pharmaceuticals in United States that focus on micronutrient therapeutics business. Founded in 2017. They cover business area such as operator, global health, essential fatty acid, micronutrient therapeutic, acid supplement, food fortifier, nutritional intervention, cell, working, age-relate breakdown, people, improve mood, caloric intake, increase fat metabolism.
2017
( 7 years old in 2024 )
Micronutrient Therapeutics
-
2850 Womble Road
Suite 100-600
San Diego, CA 92106
United States
Private
operatorglobal healthessential fatty acidmicronutrient therapeuticacid supplementfood fortifiernutritional interventioncellworkingage-relate breakdownpeopleimprove moodcaloric intakeincrease fat metabolism
* We use standard office opening hours in near Seraphina Therapeutics's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Seraphina Therapeutics is Pharmaceuticals business from United States that founded in 2017 (7 years old in 2024), Seraphina Therapeutics business is focusing on Micronutrient Therapeutics.
Seraphina Therapeutics headquarter office and corporate office address is located in 2850 Womble Road Suite 100-600 San Diego, CA 92106 United States.
Seraphina Therapeutics was founded in United States.
In 2024, Seraphina Therapeutics is currently focus on micronutrient therapeutics sector.
Above is snippet of Google Trends for "micronutrient therapeutics" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Seraphina Therapeutics, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
